Mosunetuzumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Mosunetuzumab Usage And Synthesis

Uses

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs)[1][2].

References

[1] Lihua E Budde, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40(5):481-491. DOI:10.1200/JCO.21.00931
[2] Gregory Z Ferl, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018 May;11(3):296-304. DOI:10.1111/cts.12535

Mosunetuzumab(1905409-39-3)Related Product Information

• Telisotuzumab
• Evolocumab
• Zagotenemab
• Oportuzumab Monatox
• Dacliximab
• palivizumab
• Ulocuplumab
• Teneliximab
• CNTO 148
• Trastuzumab